Last reviewed · How we verify
Dapagliflozin / metFORMIN Pill
Dapagliflozin / metFORMIN Pill is a SGLT2 inhibitor / Biguanide combination Small molecule drug developed by Tan Tock Seng Hospital. It is currently FDA-approved for Type 2 diabetes mellitus.
Dapagliflozin inhibits SGLT2 to increase urinary glucose excretion, while metformin reduces hepatic glucose production and improves insulin sensitivity.
Dapagliflozin inhibits SGLT2 to increase urinary glucose excretion, while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Dapagliflozin / metFORMIN Pill |
|---|---|
| Sponsor | Tan Tock Seng Hospital |
| Drug class | SGLT2 inhibitor / Biguanide combination |
| Target | SGLT2 (sodium-glucose cotransporter 2) / AMPK (AMP-activated protein kinase) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Dapagliflozin is an SGLT2 inhibitor that blocks reabsorption of glucose in the proximal tubule, promoting glucose excretion in urine and lowering blood glucose independently of insulin. Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. Together, they provide complementary glucose-lowering effects through distinct mechanisms.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Gastrointestinal disturbances (nausea, diarrhea)
- Hypoglycemia
- Volume depletion / orthostatic hypotension
Key clinical trials
- The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes (PHASE4)
- Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes (PHASE4)
- Dapagliflozin Effects on Epicardial Fat (PHASE4)
- EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) (PHASE3)
- Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dapagliflozin / metFORMIN Pill CI brief — competitive landscape report
- Dapagliflozin / metFORMIN Pill updates RSS · CI watch RSS
- Tan Tock Seng Hospital portfolio CI
Frequently asked questions about Dapagliflozin / metFORMIN Pill
What is Dapagliflozin / metFORMIN Pill?
How does Dapagliflozin / metFORMIN Pill work?
What is Dapagliflozin / metFORMIN Pill used for?
Who makes Dapagliflozin / metFORMIN Pill?
What drug class is Dapagliflozin / metFORMIN Pill in?
What development phase is Dapagliflozin / metFORMIN Pill in?
What are the side effects of Dapagliflozin / metFORMIN Pill?
What does Dapagliflozin / metFORMIN Pill target?
Related
- Drug class: All SGLT2 inhibitor / Biguanide combination drugs
- Target: All drugs targeting SGLT2 (sodium-glucose cotransporter 2) / AMPK (AMP-activated protein kinase)
- Manufacturer: Tan Tock Seng Hospital — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Compare: Dapagliflozin / metFORMIN Pill vs similar drugs
- Pricing: Dapagliflozin / metFORMIN Pill cost, discount & access